Pfizer Inc. Continues Its Streak, Phase 2 Breast Cancer Results Wows Investors And Researchers

(Reuters) - Pfizer Inc's experimental breast cancer drug in a clinical trial nearly doubled the amount of time patients lived without their disease getting worse, but overall survival was not yet shown to be statistically significant, researchers said.

The Phase 2 study, which involved women with the most common form of breast cancer, found that those treated with hormone drug letrozole plus Pfizer's palbociclib lived for an average of 20.2 months before their cancer progressed, compared with 10.2 months for patients given letrozole alone.

Help employers find you! Check out all the jobs and post your resume.